GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Regulus Therapeutics
Regulus is a biotech company specializing in microRNA therapeutics. Its stock price is a history of ups and downs driven by clinical trial results. The chart reflects the high volatility and risks inherent in developing drugs based on new technology.
Share prices of companies in the market segment - Dna
Regulus Therapeutics is a biotech company developing microRNA-based drugs for the treatment of rare diseases, particularly kidney disease. We've categorized it as a "DNA" company. The chart below shows how the market is valuing this cutting-edge field in genetic medicine.
Broad Market Index - GURU.Markets
Regulus Therapeutics is a biotech company developing microRNA-based drugs for the treatment of rare diseases, particularly kidney disease. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Regulus' performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
RGLS - Daily change in the company's share price Regulus Therapeutics
Regulus Therapeutics Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the clinical trials of its RNA therapeutics.
Daily change in the price of a set of shares in a market segment - Dna
Regulus Therapeutics develops microRNA-based drugs for the treatment of various diseases. This is a cutting-edge and risky area of biotechnology. The chart below illustrates the high volatility typical of this sector, reflecting the stakes associated with RGLS clinical trials.
Daily change in the price of a broad market stock, index - GURU.Markets
Regulus Therapeutics is a biotech company developing RNA interference-based drugs. The company's shares are a bet on a breakthrough in gene therapy. Their high, speculative volatility is part of the dynamic of the innovation sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Regulus Therapeutics
Regulus Therapeutics' year-to-date performance is a story of its microRNA-based drug development. Its 12-month market cap is entirely dependent on clinical trial data. The success of its lead candidate for polycystic kidney disease (PKD) could validate the potential of its unique scientific platform.
Annual dynamics of market capitalization of the market segment - Dna
Regulus, as an early-stage biotech, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about its RNA therapeutic platform. Its stock price will reflect investors' speculative belief in its potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Regulus Therapeutics is a biotech whose value is locked into its RNA platform. Its shares move with clinical trial news, not economic cycles. A sharp rise or fall amid a calm market is clear evidence that investors are betting on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Regulus Therapeutics
Regulus is a biotech company developing RNA therapeutics. Being in the clinical stage, its monthly valuation is entirely dependent on news. The results of its kidney disease drug trials are its primary driver.
Monthly dynamics of market capitalization of the market segment - Dna
Regulus Therapeutics is a biotechnology company specializing in the development of microRNA-targeted drugs for the treatment of various diseases, particularly kidney disease. The chart below shows the overall dynamics of the DNA and RNA therapeutics sector, which is one of the most advanced in modern medicine.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where clinical trial news trumps overall market trends. The chart below shows the pulse of the broader market. Does Regulus Therapeutics move in sync with the broader market, or are its R&D developments creating a completely separate story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Regulus Therapeutics
The weekly performance of Regulus, a biotech company working with microRNA, reflects cutting-edge science. Its stock price is responding to clinical trial data that may confirm the potential of its approach to treating kidney disease and other ailments.
Weekly dynamics of market capitalization of the market segment - Dna
Regulus Therapeutics develops microRNA-based drugs, a cutting-edge yet complex approach in pharmacology. This chart compares its volatile, news-driven performance with the biotech sector and helps us understand the investor confidence in its unique scientific platform.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Regulus Therapeutics is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Regulus is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
RGLS - Market capitalization of the company Regulus Therapeutics
Regulus's market capitalization tells the story of a biotech company focused on developing microRNA-based drugs. Its volatile chart reflects the long and arduous journey of scientific research. Its price action reflects investors' assessment of the progress of its leading kidney disease program.
RGLS - Share of the company's market capitalization Regulus Therapeutics within the market segment - Dna
Regulus Therapeutics is a biotech company working with microRNA. Its share of its segment's market capitalization reflects investors' faith in the potential of this cutting-edge scientific platform. The chart shows how its weight fluctuates based on clinical trial results.
Market capitalization of the market segment - Dna
Regulus Therapeutics is a biotech company developing microRNA-based drugs. The chart below shows the market capitalization of this cutting-edge sector. Its volatility reflects both the enormous scientific potential and the high risks associated with developing a fundamentally new class of drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Regulus Therapeutics develops microRNA-based drugs. The market capitalization of such biotech companies is a bet on cutting-edge science. Their volatility on the overall chart reflects how the market evaluates the potential of completely new approaches to treating diseases at the genetic level.
Book value capitalization of the company, segment and market as a whole
RGLS - Book value capitalization of the company Regulus Therapeutics
Regulus Therapeutics' foundation is its capital and patents for a platform for developing microRNA-based drugs targeting kidney and liver diseases. This is a real, scientific foundation for a new class of therapeutics. How has this innovative, yet risky, biotech asset evolved? The chart below shows its dynamics.
RGLS - Share of the company's book capitalization Regulus Therapeutics within the market segment - Dna
Regulus Therapeutics develops microRNA-based drugs, which requires advanced R&D laboratories. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation of its innovative therapeutic platform.
Market segment balance sheet capitalization - Dna
Regulus, a development-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Regulus's balance sheet is its scientific platform for developing microRNA-targeted drugs for the treatment of genetic kidney and liver diseases. The company's assets are its intellectual capital and research data. The chart below shows how this pioneer in RNA therapy stacks up in terms of assets.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Regulus Therapeutics
Regulus Therapeutics is working with microRNA, a new class of drugs. Its assets are its scientific platform and patents. Its market capitalization reflects investors' pure faith in the potential of this cutting-edge, yet still under-researched, technology. The MvsBCap_Co chart is an indicator of hope for a scientific breakthrough.
Market to book capitalization ratio in a market segment - Dna
Regulus Therapeutics is a biotech company developing microRNA-targeted drugs for the treatment of various diseases. Its market valuation in the chart is speculative and depends on the success of its clinical programs, particularly in kidney disease.
Market to book capitalization ratio for the market as a whole
Regulus Therapeutics, a biopharmaceutical company, focuses on RNA therapeutics. Its value depends almost entirely on the success of scientific developments. This chart helps assess how high the premium for breakthrough but risky biotech technologies is compared to the market average.
Debts of the company, segment and market as a whole
RGLS - Company debts Regulus Therapeutics
Regulus Therapeutics, a biotech focused on developing microRNA-based drugs, is using capital to fund its early clinical trials. This chart shows how the company is raising high-risk investments to validate its innovative scientific platform, which could be applied to the treatment of rare diseases.
Market segment debts - Dna
Regulus Therapeutics is a clinical-stage biotech company specializing in the development of microRNA-based drugs. This chart shows that the company, like its peers, funds its expensive and risky research exclusively with equity, avoiding the burden of debt until potential success.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Regulus Therapeutics
Regulus Therapeutics is a biotech company developing microRNA-based drugs. This is a cutting-edge but risky field. This chart shows how much the company relies on debt to fund its preclinical and clinical trials. It is a direct measure of its financial risk on the long road to drug development.
Market segment debt to market segment book capitalization - Dna
Regulus Therapeutics develops microRNA-based drugs to treat rare diseases. This is a cutting-edge but complex area of biotechnology. This chart illustrates how aggressively the sector uses debt to fund R&D, providing context for assessing the risks and potential of this innovative, yet unproven, platform.
Debt to book value of all companies in the market
Regulus Therapeutics, a microRNA-focused biopharmaceutical company, is at the cutting edge of science, requiring massive and risky investments in R&D. This chart, showing the overall market debt load, allows one to assess how the company's financial strategy is typical for innovative biotech companies, where the path to commercialization is long.
P/E of the company, segment and market as a whole
P/E - Regulus Therapeutics
Regulus Therapeutics is a biotech company developing microRNA-based drugs for kidney diseases. This chart shows how investors value its scientific platform. The valuation depends on the success of clinical trials and the potential of this new class of drugs.
P/E of the market segment - Dna
Developing RNA-targeted drugs, as Regulus does, is at the cutting edge of science. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Regulus, after a string of failures, is considered a high-risk research project, and its value depends on the success of its current clinical programs.
P/E of the market as a whole
Regulus Therapeutics is a biotech company developing microRNA-based drugs. Its valuation is a pure bet on its scientific platform. It has no connection to the general economic cycles depicted by this chart. Regulus's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Regulus Therapeutics
This chart for Regulus Therapeutics, a biopharmaceutical company developing microRNA-based drugs, shows market expectations for its clinical programs. It reflects investor confidence in the potential of this innovative platform for treating kidney diseases and other conditions.
%20P%2FE%20Regulus%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Regulus-Therapeutics&v=1772553603458 "Chart of the company's future (projected) P/E Regulus Therapeutics")
Future (projected) P/E of the market segment - Dna
Regulus Therapeutics is a biopharmaceutical company specializing in the discovery and development of microRNA-targeted drugs for the treatment of kidney and liver diseases. This chart shows forecasts for the biotech sector. This helps compare how the market views Regulus's innovative, yet risky, approach to gene regulation and the potential of its developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772553603482 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Regulus Therapeutics Inc. is a biotech company developing microRNA-based drugs. This is a cutting-edge scientific approach. The company's valuation is a bet on the success of its scientific platform. This chart shows how willing investors are to fund fundamental research that could change treatment approaches.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772553603816 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Regulus Therapeutics
Regulus Therapeutics is a biopharmaceutical company developing microRNA-based drugs for rare diseases. While in the clinical stage, it is incurring significant losses. This chart illustrates the financial implications of cutting-edge research, which carries high risks but also offers the potential to create new classes of drugs.
Profit of companies in the market segment - Dna
Regulus Therapeutics is a biotech company developing microRNA-targeted drugs for the treatment of various diseases. This graph, which shows the sector's profitability, illustrates how science is exploring new approaches to gene regulation. Their research focuses on treating kidney diseases, and their success depends on the results of clinical trials.
Overall market profit
Regulus Therapeutics develops microRNA-based drugs for the treatment of various diseases, particularly rare kidney diseases. It is an innovative scientific platform. Funding for such cutting-edge, yet risky, research depends on the overall investment climate. Growing corporate profits, as shown in this chart, increase investor appetite for biotech.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Regulus Therapeutics
Regulus Therapeutics is developing microRNA-based drugs targeting kidney and liver diseases. This innovative approach has the potential to transform treatment standards. This graph represents analysts' expectations for the success of clinical trials and the potential of this cutting-edge technology for treating complex diseases.
%20profit%20of%20the%20company%20Regulus%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Regulus-Therapeutics&v=1772553604176 "Graph of future (projected) profit of the company Regulus Therapeutics")
Future (predicted) profit of companies in the market segment - Dna
Regulus Therapeutics is a biotech company developing microRNA-targeted drugs for the treatment of various diseases. After a series of failures, the company has focused on a new direction. Its future depends on the success of its current programs. This timeline for the biotech sector provides only a general overview; Regulus's key focus is on its own clinical data.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772553604261 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Regulus Therapeutics is a biotech company developing microRNA-based drugs. Its success depends on scientific breakthroughs. The overall profit forecast shown in this chart influences the overall investment climate in biotech and the willingness of investors to fund early-stage companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772553604344 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Regulus Therapeutics
Regulus Therapeutics is a biotech company developing microRNA-targeted drugs for rare diseases. For a clinical-stage company, this chart is key. It shows how investors evaluate its unique scientific platform and future revenue potential, placing their bets on this new class of drugs.
P/S market segment - Dna
Regulus Therapeutics is developing a new class of microRNA-based drugs for the treatment of kidney and liver diseases. The company's valuation is based on the potential of its unique scientific platform. This chart, which reflects the average valuation in the biotech industry, helps investors understand how expectations for Regulus' innovative technology align with overall industry trends.
P/S of the market as a whole
Regulus Therapeutics is a biotech company focused on the discovery and development of microRNA-targeted drugs for the treatment of kidney diseases. This chart, which reflects revenue estimates for real businesses, highlights that Regulus's valuation is a bet on its unique scientific platform and the potential to create a new class of drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Regulus Therapeutics
Regulus Therapeutics is a clinical-stage biotech focused on developing microRNA-targeted drugs for rare diseases. This approach is cutting-edge, but risky. This chart reflects investor hopes that its scientific platform will prove its worth in clinical trials.
%20P%2FS%20Regulus%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Regulus-Therapeutics&v=1772553604939 "The graph of the company's future (projected) P/S Regulus Therapeutics")
Future (projected) P/S of the market segment - Dna
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company developing microRNA-targeted therapies for the treatment of a wide range of diseases. This chart reflects average revenue expectations in the biotech sector and provides insight into the market's appreciation of Regulus's innovative scientific platform.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772553604993 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Regulus Therapeutics is developing a new generation of microRNA-targeted drugs for the treatment of a wide range of diseases. This chart shows the market's collective revenue expectations. The company's innovative platform could open up entirely new treatment approaches, fueling investor optimism about the long-term prospects of biotech.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772553605071 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Regulus Therapeutics
This chart illustrates the revenue of Regulus Therapeutics, a clinical-stage biopharmaceutical company developing microRNA-targeted drugs. Its revenue is generated not from sales but from partnership fees, reflecting the progress of clinical trials and the commercial potential of its platform.
Sales of companies in the market segment - Dna
Regulus Therapeutics is a biotech company developing a new class of microRNA-based drugs for the treatment of kidney and liver diseases. This chart illustrates the growth of the gene medicine market. Regulus' innovative approach could lead to breakthrough treatments targeting previously inaccessible biological targets, expanding opportunities for the entire industry.
Overall market sales
Regulus Therapeutics is a biotech company developing microRNA-based drugs. Its market capitalization depends on progress in clinical trials. The overall economic situation, reflected in this chart, influences the availability of venture capital for funding fundamental research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Regulus Therapeutics
Regulus Therapeutics is a biotech company developing microRNA-targeted drugs for the treatment of various diseases. Future revenue depends on the success of its innovative scientific platform. The chart reflects analysts' confidence in the potential of this new class of drugs.
%20sales%20of%20the%20company%20Regulus%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Regulus-Therapeutics&v=1772553605464 "Schedule of future (projected) sales of the company Regulus Therapeutics")
Future (projected) sales of companies in the market segment - Dna
Regulus Therapeutics is a biotechnology company specializing in the discovery and development of microRNA-targeted drugs for the treatment of a wide range of diseases. This chart shows the forecast for the entire DNA and RNA therapeutics market, where Regulus is working at the forefront of science, striving to create a new class of drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772553605540 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Regulus Therapeutics is a biotech company developing microRNA-targeted drugs for the treatment of kidney diseases and other rare conditions. Its valuation is dependent on the success of clinical trials. This schedule, reflecting sentiment in the biotech sector, impacts the company's ability to attract funding to continue its research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772553605636 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Regulus Therapeutics
Regulus Therapeutics is a biotech company specializing in developing microRNA-targeted drugs for the treatment of various diseases. Being in the clinical stage, it incurs significant research expenses. This chart shows its net losses—investments in a groundbreaking scientific platform that could unlock new therapeutic approaches.
Market segment marginality - Dna
Regulus Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted drugs for the treatment of kidney diseases. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors analyze it to assess the potential of their unique scientific platform.
Market marginality as a whole
Regulus Therapeutics is a biotech company focused on developing drugs that target microRNAs for the treatment of various diseases, particularly rare kidney diseases. This overall profitability curve is irrelevant to them. Their value and future depend solely on the results of their clinical trials and the potential of their scientific platform.
Employees in the company, segment and market as a whole
Number of employees in the company Regulus Therapeutics
Regulus Therapeutics is a biotech company specializing in the development of drugs targeting microRNAs. It operates with a small team of scientists focused on early-stage research. This schedule reflects its model, which focuses on scientific discovery rather than large-scale operations.
Share of the company's employees Regulus Therapeutics within the market segment - Dna
Regulus Therapeutics is a pioneer in developing microRNA-targeted drugs for the treatment of various diseases. This chart reflects its focused scientific approach. It shows the size of the research team working to advance this new class of drugs, particularly for the treatment of rare kidney diseases.
Number of employees in the market segment - Dna
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing microRNA-targeted drugs. This chart shows the dynamics of employment in the cutting-edge field of gene therapy. The growing number of scientists here signals progress in clinical trials and the potential for creating a new class of drugs for rare diseases.
Number of employees in the market as a whole
Regulus Therapeutics is developing microRNA-based drugs. This cutting-edge scientific field requires significant investment. General economic stability, illustrated by this chart, influences investor willingness to invest in high-risk biotech companies whose developments are in the early stages of research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Regulus Therapeutics (RGLS)
Regulus Therapeutics is a biotech company focused on microRNA-targeted drugs for kidney disease. It is a clinical-stage R&D company. The chart shows that the company's market value is a valuation of its scientific platform. The company's market capitalization per employee is extremely high, reflecting the patent potential and intellectual capital of its small team of scientists.
%20of%20the%20company%20Regulus%20Therapeutics%20(RGLS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Regulus-Therapeutics-RGLS&v=1772553606140 "Chart of market capitalization per employee (in thousands of dollars) of the company Regulus Therapeutics (RGLS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Regulus Therapeutics is a biotech company specializing in the development of microRNA-targeted drugs for the treatment of various diseases. Its valuation is based on the potential of its scientific platform. This chart demonstrates the high market valuation of its advanced technologies and intellectual property per scientist.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772553606283 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Regulus Therapeutics is a biopharmaceutical company developing microRNA-targeted drugs for the treatment of diseases. The chart illustrates the valuation of their unique scientific platform. It shows how the market views their innovative approach to gene regulation, which is being developed by a small scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772553606403 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Regulus Therapeutics (RGLS)
Regulus Therapeutics is a clinical-stage biotech company specializing in developing microRNA-targeted drugs for rare diseases. This chart shows R&D. This chart shows the company's capital burn rate: the amount of capital the company spends on each scientist trying to prove the efficacy of their innovative platform.
%20Chart%20Regulus%20Therapeutics%20(RGLS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Regulus-Therapeutics-RGLS&v=1772553606548 "Company Profit Per Employee (in thousands of dollars) Chart Regulus Therapeutics (RGLS)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Regulus Therapeutics is a clinical-stage biotech company specializing in the development of microRNA-targeted drugs. This is at the cutting edge of science. This metric (loss per employee) reflects the high cost of R&D for this new drug platform.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772553606967 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Regulus Therapeutics (RGLS) is a clinical-stage biotech company specializing in the treatment of kidney diseases. It is an R&D company and is not profitable. This chart shows the company's capital burn rate: the operating loss per research team developing the new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772553607016 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Regulus Therapeutics (RGLS)
Regulus Therapeutics is a biotech company focused on developing microRNA-targeted therapeutics. This chart reflects the progress of monetizing its scientific platform. Revenue growth at this stage is likely due to upfront payments from major partners interested in its unique approach to treating diseases.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Regulus-Therapeutics-RGLS&v=1772553607056 "Sales chart per company employee Regulus Therapeutics (RGLS)")
Sales per employee in the market segment - Dna
Regulus Therapeutics (RGLS) is a biotech company specializing in the development of microRNA-targeted drugs, a new way to treat diseases, including kidney disease. This chart shows how productive their R&D team is. It measures revenue (from partnerships) per scientist, reflecting the value of their scientific platform.
Sales per employee for the market as a whole
Regulus Therapeutics (RGLS) is a clinical-stage biotech company specializing in microRNA-targeted drugs for kidney diseases. The company has no commercial revenue yet. This chart illustrates a typical R&D situation: the entire research team is working on developing future drugs, consuming investment capital.
Short shares by company, segment and market as a whole
Shares shorted by company Regulus Therapeutics (RGLS)
Regulus Therapeutics is a biotech company working on microRNA-targeted drugs. The bearish sentiment shown by this chart is a bet that its scientific platform, while interesting, will fail to produce effective or safe drugs and will fail in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Regulus-Therapeutics-RGLS&v=1772553607260 "Short Shares Chart for the Company Regulus Therapeutics (RGLS)")
Shares shorted by market segment - Dna
This chart measures investor skepticism toward the entire early-stage biotech segment. Regulus Therapeutics focuses on microRNA. For such companies, industry sentiment is critical: high short interest across the sector indicates that investors lack confidence in the scientific platforms and expect clinical trial failures.
Shares shorted by the overall market
Regulus is a biotech company working in a complex R&D field (microRNA). This chart illustrates the general market "fear." When investors panic, they're unwilling to fund such long-term research projects. They see their cash being burned and sell off their shares, fearing the company won't survive to commercial success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Regulus Therapeutics (RGLS)
Regulus Therapeutics (RGLS) is a biotech company working on microRNA-based drugs for kidney disease. This is a binary bet on the success of their trials. This chart measures the market's "temperature," showing when the stock is "overheated" (above 70) in anticipation of a breakout or "oversold" (below 30) due to delays or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Regulus-Therapeutics-RGLS&v=1772553607633 "RSI 14 indicator chart for the company's stock Regulus Therapeutics (RGLS)")
RSI 14 Market Segment - Dna
Regulus Therapeutics is a biotech company specializing in the development of microRNA-based drugs. Their R&D is aimed at treating kidney disease (ADPKD) and other rare diseases. This chart reflects the overall sentiment in the genetic engineering sector and helps assess how overheated this futuristic biotech segment is.
RSI 14 for the overall market
Regulus (RGLS) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the opportunity to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RGLS (Regulus Therapeutics)
Regulus (RGLS) is a biotech company developing microRNA-based drugs for the treatment of diseases, particularly rare kidney diseases. This chart shows the average 12-month forecast. It reflects analysts' speculative valuation of this scientific platform and their expectations for clinical trial data for its lead candidate.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RGLS-Regulus-Therapeutics&v=1772553607775 "A chart showing analyst consensus forecasts for the expected stock price. RGLS (Regulus Therapeutics)")
The difference between the consensus estimate and the actual stock price RGLS (Regulus Therapeutics)
Regulus (RGLS) is a biotech company specializing in microRNAs—drugs that "turn off" genes that cause diseases (such as polycystic kidney disease). This chart shows the difference between the market valuation and the consensus estimate. It reveals whether experts believe in this complex yet cutting-edge R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RGLS-Regulus-Therapeutics&v=1772553607815 "A chart showing the difference between the consensus forecast and the actual stock price. RGLS (Regulus Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Dna
Regulus is an R&D biotech company developing anti-miRNA drugs that target microRNAs for the treatment of rare kidney diseases. This R&D is at the cutting edge of science. This chart displays analysts' overall expectations for the *entire* DNA technology sector. It shows how much confidence experts have in this R&D platform.
Analysts' consensus forecast for the overall market share price
Regulus Therapeutics (RGLS) is a clinical-stage biopharmaceutical company developing a microRNA therapy for kidney disease. This is a high-risk research endeavor. This chart shows the overall risk appetite in the market. It is an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Regulus Therapeutics
Regulus is a biotech microRNA hunter. Their specialty is the R&D of antisense drugs, which target microRNAs (regulators) rather than genes, for the treatment of rare diseases (Alagille disease) and kidney diseases. This chart is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Dna
Regulus Therapeutics (RGLS) is a biotech company focused on microRNAs. They develop drugs that target these microRNAs to treat, for example, kidney disease. This chart compares their composite index to the sector, showing how their microRNA R&D platform outperforms the competition.
The AKIM Index for the overall market
Regulus Therapeutics is a biotech company focused on microRNA-based therapies for kidney disease (polycystic kidney disease). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research compares to overall economic trends in nephrology.
